Avoro Capital Advisors’s MoonLake Immunotherapeutics MLTX Stock Holding History

Avoro Capital Advisors’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,000,000	Closed	-$14.3M	–	40
2025 Q3	$14.3M	Sell	2,000,000 -2,150,000	-52%	-$112M	0.19%	27
2025 Q2	$196M	Buy	4,150,000 +1,379,900	+50%	+$56.2M	3.43%	9
2025 Q1	$108M	Hold	2,770,100	–	–	1.69%	17
2024 Q4	$150M	Hold	2,770,100	–	–	2.12%	15
2024 Q3	$140M	Buy	2,770,100 +100	+0%	+$4.69K	2.04%	16
2024 Q2	$122M	Buy	2,770,000 +190,000	+7%	+$8.05M	1.62%	17
2024 Q1	$130M	Hold	2,580,000	–	–	1.51%	21
2023 Q4	$156M	Buy	2,580,000 +580,001	+29%	+$29.9M	2.15%	17
2023 Q3	$114M	Buy	1,999,999 +274,999	+16%	+$15.2M	1.78%	16
2023 Q2	$88M	Buy	+1,725,000	New	+$46.4M	1.19%	19

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Avoro Capital Advisors's MLTX Position: Q4 2025 in Review

Avoro Capital Advisors sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2025, closing a stake of 2,000,000 shares — an estimated $14.3M sold.

Avoro Capital Advisors first reported a position in MLTX in Q2 2023 and held it in 10 quarters. The position peaked at $196M in Q2 2025. 130 funds tracked by Wall St. Rank hold MLTX as of Q4 2025.

Avoro Capital Advisors reported no remaining MoonLake Immunotherapeutics position as of Q4 2025 after selling out during the quarter.
Avoro Capital Advisors sold 2,000,000 MoonLake Immunotherapeutics shares in Q4 2025, an estimated $14.3M.
Avoro Capital Advisors first reported a position in MoonLake Immunotherapeutics in Q2 2023 and held it in 10 quarters.
Avoro Capital Advisors's MoonLake Immunotherapeutics position peaked at $196M in Q2 2025.
130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2025.

Based on Avoro Capital Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.